Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 in Patients With Type 2 Diabetes Mellitus Treated With Metformin

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions

Type 2 Diabetes

Interventions

DRUG

AZD1656

Subjects will be treated with tolerable dose twice daily for another 24 days.

DRUG

Placebo

Subjects will be treated with tolerable dose twice daily for another 24 days.

Trial Locations (1)

Research Site, San Antonio